Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H30N8O4.C6H8O7 |
| Molecular Weight | 698.6804 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.COCCNC1=C(C=NC(NC(=O)N2CCCC3=C2N=C(C=O)C(CN4CCN(C)CC4=O)=C3)=C1)C#N
InChI
InChIKey=PQMNMOKXXAMVFR-UHFFFAOYSA-N
InChI=1S/C25H30N8O4.C6H8O7/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22;7-3(8)1-6(13,5(11)12)2-4(9)10/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
| Molecular Formula | C6H8O7 |
| Molecular Weight | 192.1235 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C25H30N8O4 |
| Molecular Weight | 506.5569 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://clinicaltrials.gov/ct2/show/NCT02325739Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2015059668A1
Sources: https://clinicaltrials.gov/ct2/show/NCT02325739
Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2015059668A1
FGF-401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, FGF401 binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF-401 is an FGFR4 inhibitor in phase I/II clinical studies at Novartis for the treatment of positive FGFR4 and KLB expression solid tumors and hepatocellular carcinoma.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3973 Sources: https://encrypted.google.com/patents/WO2015059668A1 |
7.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
426.59 ng/mL |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
748.76 ng/mL |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
991.13 ng/mL |
80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1329.72 ng/mL |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
851.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35655320/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2084.6 ng × h/mL |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3212.66 ng × h/mL |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4284.35 ng × h/mL |
80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6214.09 ng × h/mL |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35655320/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.9 h |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.78 h |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.12 h |
80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.97 h |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: PEMBROLIZUMAB |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35655320/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ROBLITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02325739
Unknown
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://encrypted.google.com/patents/WO2015059668A1
The effect of compounds (FGF-401) on cell proliferation is assessed using HuH-7 hepatocellular carcinoma cells obtained from the Japanese Collection of Research Bioresources Cell Bank (Cat# JCRB0403) and cultured in the vendor-recommended medium (DMEM high glucose (Amimed Cat# 1 -26F01 -I), 10% foetal calf serum (Invitrogen Cat# 16140-071 ), 1 mM sodium pyruvate (Amimed Cat# 5-60F00-H), 1x Penicillin/Streptomycin (Amimed Cat# 4-01 F00-H)) at 37°C in a humidified 5% C02 incubator. Specifically, 5000 cells/well were seeded in 96-well tissue culture plates (TPP Cat# 92696) in a total media volume of 100 μΙ/well and increasing compound dilutions or DMSO were added 24 hours thereafter in triplicates. 72 hours after compound addition, cells were fixed by adding 25 [ Uwe\\ of 20% glutaraldehyde (Sigma Aldrich Cat# G400-4) and incubated for 10 minutes at room temperature. Cells were washed three times with H20, 200 [ Uwe\\ and stained with 100 [ Uwe\\ 0.05% methylene blue (ABCR GmbH Cat# AB1 17904) for 10 minutes at room temperature. Cells were washed 3 times with H20, 200 ML/well and then lysed by adding 200 ML/well of 3% HCI (Fluka Cat# 84422) for 30 minutes at room temperature with shaking. Optical density was measured at A650 nm.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:59:10 GMT 2025
by
admin
on
Mon Mar 31 22:59:10 GMT 2025
|
| Record UNII |
2GP4K035FI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2GP4K035FI
Created by
admin on Mon Mar 31 22:59:10 GMT 2025 , Edited by admin on Mon Mar 31 22:59:10 GMT 2025
|
PRIMARY | |||
|
1708971-60-1
Created by
admin on Mon Mar 31 22:59:10 GMT 2025 , Edited by admin on Mon Mar 31 22:59:10 GMT 2025
|
PRIMARY | |||
|
2012534-92-6
Created by
admin on Mon Mar 31 22:59:10 GMT 2025 , Edited by admin on Mon Mar 31 22:59:10 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
133082760
Created by
admin on Mon Mar 31 22:59:10 GMT 2025 , Edited by admin on Mon Mar 31 22:59:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |